Matrix metalloproteinase (MMP-1) and tissue inhibitor of MMP in peritoneal fluids and sera and correlation with peritoneal adhesions

Fertility and Sterility

Volumn 76, Issue 6, 2001, Pages 1207-1211

  Chegini, Nasser ^a   Kotseos, Kristina ^a   Bennett, Barbara ^a   Diamond, Michael P ^b   Holmdahl, Lena ^c   Burns, James ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d GENZYME CORPORATION   (United States)

Author keywords

MMP 1; Peritoneal adhesion; Peritoneal fluid; TIMP 1 serum

Indexed keywords

INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGE; AGED; APPENDECTOMY; ARTICLE; BLOOD LEVEL; CESAREAN SECTION; CONTROLLED STUDY; CYSTECTOMY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MALE; PERITONEAL FLUID; PERITONEUM ADHESION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; SERUM; SEX DIFFERENCE; UTERINE TUBE LIGATION;

ABDOMEN; ADHESIONS; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PERITONEAL DISEASES; POSTOPERATIVE COMPLICATIONS; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; WOUND HEALING;

EID: 0035199612     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)02874-6     Document Type: Article

References (34)

1. Matrix metalloproteinases in repair
2. Wound repair. Overview and general consideration
3. Proteolysis and cell migration: Creating a path?
4. Matrix metalloproteinases and their tissue inhibitors in endometrial remodeling and menstruation
5. Temporal activity of plasminogen activators and matrix metalloproteinases during cutaneous wound repair
6. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair
7. Matrix metalloproteinases in skin
8. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
9. Complex role of matrix metalloproteinases in angiogenesis
10. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers
11. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers
12. Expression of matrix metalloproteinase-2 and -9 during early human wound healing
13. Role of matrix metalloproteinases in healing of colonic anastomosis
14. Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase-9
15. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
16. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases
17. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing
18. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor β1
19. Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells
20. Expression of matrix metalloproteinase and tissue inhibitor of MMP in serosal tissue of intraperitoneal organs and adhesions
21. Matrix metalloproteinase (MMP-3), tissue inhibitor of MMP (TIMP-2) expression in intraperitoneal environment and their relation to adhesion development
22. Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases, and their inhibitors in rat models for adhesion formation and endometriosis: Potential GnRH-a-regulated mechanisms reducing adhesion formation
23. Tissue inhibitor of metalloproteinase-1 concentrations are attenuated in peritoneal fluid and sera of women with endometriosis and restored in sera by gonadotropin-releasing hormone agonist therapy
24. Peritonitis increases MMP-9 activity in peritoneal effluent from CAPD patients
25. Matrix metalloproteinases and their tissue inhibitors in antegradely shed menstruum and peritoneal fluid
26. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): A blinded, prospective, randomized, multicenter clinical study
27. The role of growth factors in peritoneal healing: Transforming growth factor β (TGF-β)
28. The relevance of the peritoneal fluid in endometriosis-associated infertility
29. Peritoneal exposure to surgical glove powders differentially modulate the inflammatory and immune related cytokines production during surgically-induced adhesion formation
30. Differential expression of TGF-β1 and TGF-β3 in serosal tissues of human intraperitoneal organs and peritoneal adhesions
31. Differential expression of integrin αv and β3 in serosal tissue of human intraperitoneal organs and adhesion
32. Adhesion-related hospital readmissions after abdominal and pelvic surgery: A retrospective cohort study
33. The impact of adhesions on hospital readmissions over ten years after 8849 open gynaecological operations: An assessment from the Surgical and Clinical Adhesions Research Study
34. Peritoneal fluid cytokine and eicosanoid levels and their relation to the incidence of peritoneal adhesion